Showing 81 - 100 results of 42,734 for search '(( 5 non decrease ) OR ((( 50 mg decrease ) OR ( 5 ((mean decrease) OR (we decrease)) ))))', query time: 0.86s Refine Results
  1. 81
  2. 82

    Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  3. 83

    Pharmacological Mechanism of the Non-hallucinogenic 5‑HT<sub>2A</sub> Agonist Ariadne and Analogs by Michael J. Cunningham (14267038)

    Published 2022
    “…Compared to DOM, Ariadne shows lower signaling potency and efficacy in multiple signaling pathways examined (G<sub>q</sub>, G<sub>11</sub>, and β-arrestin2) coupled to 5-HT<sub>2A</sub> receptors. We confirmed the shift in signaling for an α-propyl analog and provide a molecular docking rationale for the progressive decrease in signaling potency with the growing length of the α-substituent. …”
  4. 84

    Pharmacological Mechanism of the Non-hallucinogenic 5‑HT<sub>2A</sub> Agonist Ariadne and Analogs by Michael J. Cunningham (14267038)

    Published 2022
    “…Compared to DOM, Ariadne shows lower signaling potency and efficacy in multiple signaling pathways examined (G<sub>q</sub>, G<sub>11</sub>, and β-arrestin2) coupled to 5-HT<sub>2A</sub> receptors. We confirmed the shift in signaling for an α-propyl analog and provide a molecular docking rationale for the progressive decrease in signaling potency with the growing length of the α-substituent. …”
  5. 85
  6. 86
  7. 87
  8. 88
  9. 89
  10. 90
  11. 91
  12. 92
  13. 93
  14. 94

    Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>In the recurrence group, CRT (μm ± standard deviation) significantly decreased from 546.1 ± 117.0 μm preoperatively to 317.1 ± 46.9, 317.8 ± 55.6, 290.8 ± 33.5, 342.9 ± 82.2, 333.0 ± 84.2, and 349.8 ± 76.9 μm at 1, 3, 6, 12, 24, and 36 months, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  15. 95
  16. 96
  17. 97
  18. 98

    Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…CRT in the recurrence group significantly decreased from 546.1 ± 117.0 μm preoperatively to 317.1 ± 46.9, 317.8 ± 55.6, 290.8 ± 33.5, 342.9 ± 82.2, 333.0 ± 84.2, and 349.8 ± 76.9 μm at 1, 3, 6, 12, 24, and 36 months postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”
  19. 99
  20. 100